Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Cancer ; 89(6): 1116-22, 2003 Sep 15.
Article in English | MEDLINE | ID: mdl-12966435

ABSTRACT

Proteolysis-inducing factor (PIF), isolated from a cachexia-inducing murine tumour, has been shown to stimulate protein breakdown in C(2)C(12) myotubes. The effect was attenuated by the specific proteasome inhibitor lactacystin and there was an elevation of proteasome 'chymotrypsin-like' enzyme activity and expression of 20S proteasome alpha-subunits at concentrations of PIF between 2 and 16 nM. Higher concentrations of PIF had no effect. The action of PIF was attenuated by eicosapentaenoic acid (EPA) (50 microM). At a concentration of 4 nM, PIF induced a transient decrease in IkappaBalpha levels after 30 min incubation, while no effect was seen at 20 nM PIF. The level of IkappaBalpha, an NF-kappaB inhibitory protein, returned to normal after 60 min. Depletion of IkappaBalpha from the cytosol was not seen in myotubes pretreated with EPA, suggesting that the NF-kappaB/IkappaB complex was stabilised. At concentrations between 2 and 8 nM, PIF stimulated an increased nuclear migration of NF-kappaB, which was not seen in myotubes pretreated with EPA. The PIF-induced increase in chymotrypsin-like enzyme activity was also attenuated by the NF-kappaB inhibitor peptide SN50, suggesting that NF-kappaB may be involved in the PIF-induced increase in proteasome expression. The results further suggest that EPA may attenuate protein degradation induced by PIF, at least partly, by preventing NF-kappaB accumulation in the nucleus.


Subject(s)
Blood Proteins/pharmacology , Cysteine Endopeptidases/metabolism , Fungal Proteins , Multienzyme Complexes/metabolism , Muscle Fibers, Skeletal/drug effects , NF-kappa B/metabolism , Ubiquitins/metabolism , Animals , Blotting, Western , Cachexia/metabolism , Cells, Cultured/drug effects , Cells, Cultured/metabolism , Chymotrypsin/metabolism , Colonic Neoplasms/genetics , Colonic Neoplasms/metabolism , Cysteine Endopeptidases/genetics , DNA Primers/chemistry , DNA Primers/genetics , Eicosapentaenoic Acid/pharmacology , Electrophoretic Mobility Shift Assay , Female , Gene Expression Regulation , I-kappa B Proteins/metabolism , Mice , Mice, Knockout , Multienzyme Complexes/genetics , Muscle Fibers, Skeletal/metabolism , NF-KappaB Inhibitor alpha , NF-kappa B/antagonists & inhibitors , NF-kappa B/genetics , Proteasome Endopeptidase Complex , Proteins/metabolism , Proteoglycans , Transcription Factors/deficiency , Transcription Factors/genetics , Transcription Factors/metabolism
2.
Br J Cancer ; 89(4): 737-45, 2003 Aug 18.
Article in English | MEDLINE | ID: mdl-12915888

ABSTRACT

The potential role of 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) as an intracellular signal for increased protein catabolism and induction of the expression of key components of the ubiquitin-proteasome proteolytic pathway induced by a tumour cachectic factor, proteolysis-inducing factor has been studied in murine C(2)C(12) myotubes. 15(S)-HETE induced protein degradation in these cells with a maximal effect at concentrations between 78 and 312 nM. The effect was attenuated by the polyunsaturated fatty acid, eicosapentaenoic acid (EPA). There was an increase in 'chymotrypsin-like' enzyme activity, the predominant proteolytic activity of the proteasome, in the same concentration range as that inducing total protein degradation, and this effect was also attenuated by EPA. 15(S)-hydroxyeicosatetraenoic acid also increased maximal expression of mRNA for proteasome subunits C2 and C5, as well as the ubiquitin-conjugating enzyme, E2(14k), after 4 h incubation, as determined by quantitative competitive RT-PCR. The concentrations of 15-HETE affecting gene expression were the same as those inducing protein degradation. Western blotting of cellular supernatants of myotubes treated with 15(S)-HETE for 24 h showed increased expression of p42, an ATPase subunit of the regulatory complex at similar concentrations, as well as a decrease in expression of myosin in the same concentration range. 15(S)-hydroxyeicosatetraenoic acid activated binding of nuclear factor-kappaB (NF-kappaB) in the myotube nucleus and stimulated degradation of I-kappaBalpha. The effect on the NF-kappaB/I-kappaBalpha system was attenuated by EPA. In addition, the NF-kappaB inhibitor peptide SN50 attenuated the increased chymotrypsin-like enzyme activity in the presence of 15(S)-HETE. These results suggest that 15(S)-HETE induces degradation of myofibrillar proteins in differentiated myotubes through an induction of an increased expression of the regulatory components of the ubiquitin-proteasome proteolytic pathway possibly through the intervention of the nuclear transcription factor NF-kappaB, and that this process is inhibited by EPA.


Subject(s)
Cysteine Endopeptidases/metabolism , Hydroxyeicosatetraenoic Acids/pharmacology , Multienzyme Complexes/metabolism , Muscle Fibers, Skeletal/drug effects , Muscle, Skeletal/drug effects , Ubiquitins/metabolism , Animals , Blotting, Western , Cells, Cultured , Cysteine Endopeptidases/genetics , DNA Primers/chemistry , Eicosapentaenoic Acid/pharmacology , Electrophoretic Mobility Shift Assay , I-kappa B Proteins/genetics , I-kappa B Proteins/metabolism , Mice , Multienzyme Complexes/genetics , Muscle Fibers, Skeletal/metabolism , Muscle, Skeletal/metabolism , Myosins/metabolism , NF-kappa B/genetics , NF-kappa B/metabolism , Proteasome Endopeptidase Complex , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction
3.
Biochem Biophys Res Commun ; 285(3): 598-602, 2001 Jul 20.
Article in English | MEDLINE | ID: mdl-11453634

ABSTRACT

A number of acute wasting conditions are associated with an upregulation of the ubiquitin-proteasome system in skeletal muscle. Eicosapentaenoic acid (EPA) is effective in attenuating the increased protein catabolism in muscle in cancer cachexia, possibly due to inhibition of 15-hydroxyeicosatetraenoic acid (15-HETE) formation. To determine if a similar pathway is involved in other catabolic conditions, the effect of EPA on muscle protein degradation and activation of the ubiquitin-proteasome pathway has been determined during acute fasting in mice. When compared with a vehicle control group (olive oil) there was a significant decrease in proteolysis of the soleus muscles of mice treated with EPA after starvation for 24 h, together with an attenuation of the proteasome "chymotryptic-like" enzyme activity and the induction of the expression of the 20S proteasome alpha-subunits, the 19S regulator and p42, an ATPase subunit of the 19S regulator in gastrocnemius muscle, and the ubiquitin-conjugating enzyme E2(14k). The effect was not shown with the related (n-3) fatty acid docosahexaenoic acid (DHA) or with linoleic acid. However, 2,3,5-trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504), an inhibitor of 5-, 12- and 15-lipoxygenases also attenuated muscle protein catabolism, proteasome "chymotryptic-like" enzyme activity and expression of proteasome 20S alpha-subunits in soleus muscles from acute fasted mice. These results suggest that protein catabolism in starvation and cancer cachexia is mediated through a common pathway, which is inhibited by EPA and is likely to involve a lipoxygenase metabolite as a signal transducer.


Subject(s)
Cysteine Endopeptidases/metabolism , Eicosapentaenoic Acid/administration & dosage , Endopeptidases , Multienzyme Complexes/metabolism , Starvation/drug therapy , Starvation/metabolism , Ubiquitins/metabolism , Acute Disease , Adenosine Triphosphatases/metabolism , Administration, Oral , Animals , Benzoquinones/pharmacology , Docosahexaenoic Acids/administration & dosage , Enzyme Activation/drug effects , Female , In Vitro Techniques , Linoleic Acid/administration & dosage , Lipoxygenase Inhibitors/pharmacology , Mice , Mice, Inbred Strains , Multienzyme Complexes/antagonists & inhibitors , Muscle, Skeletal/drug effects , Muscle, Skeletal/metabolism , Proteasome Endopeptidase Complex , Signal Transduction
4.
Cancer Res ; 61(9): 3604-9, 2001 May 01.
Article in English | MEDLINE | ID: mdl-11325828

ABSTRACT

Cancer cachexia is characterized by selective depletion of skeletal muscle protein reserves. Soleus muscles from mice bearing a cachexia-inducing tumor (MAC16) showed an increased protein degradation in vitro, as measured by tyrosine release, when compared with muscles from nontumor-bearing animals. After incubation under conditions that modify different proteolytic systems, lysosomal, calcium-dependent, and ATP-dependent proteolysis were found to contribute to the elevated protein catabolism. Treatment of mice bearing the MAC16 tumor with the polyunsaturated fatty acid, eicosapentaenoic acid (EPA), attenuated loss of body weight and significantly suppressed protein catabolism in soleus muscles through an inhibition of an ATP-dependent proteolytic pathway. The ATP-ubiquitin-dependent proteolytic pathway is considered to play a major role in muscle catabolism in cachexia, and functional proteasome activity, as determined by "chymotrypsin-like" enzyme activity, was significantly elevated in gastrocnemius muscle of mice bearing the MAC16 tumor as weight loss progressed. When animals bearing the MAC16 tumor were treated with EPA, functional proteasome activity was completely suppressed, together with attenuation of the expression of 20S proteasome alpha-subunits and the p42 regulator, whereas there was no effect on the expression of the ubiquitin-conjugating enzyme (E2(14k)). These results suggest that EPA induces an attenuation of the up-regulation of proteasome expression in cachectic mice, and this was correlated with an increase in myosin expression, confirming retention of contractile proteins. EPA also inhibited growth of the MAC16 tumor in a dose-dependent manner, and this correlated with suppression of the expression of the 20S proteasome alpha-subunits in tumor cells, suggesting that this may be the mechanism of tumor growth inhibition. Thus EPA antagonizes loss of skeletal muscle proteins in cancer cachexia by down-regulation of proteasome expression, and this may also be the mechanism for inhibition of tumor growth.


Subject(s)
Cachexia/metabolism , Eicosapentaenoic Acid/pharmacology , Leucine/analogs & derivatives , Muscle Proteins/metabolism , Muscle, Skeletal/metabolism , Adenocarcinoma/complications , Adenocarcinoma/metabolism , Adenosine Triphosphate/metabolism , Animals , Cachexia/drug therapy , Cachexia/etiology , Calcium/metabolism , Colonic Neoplasms/complications , Colonic Neoplasms/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Female , Lysosomes/drug effects , Lysosomes/metabolism , Mice , Muscle, Skeletal/drug effects , Peptide Hydrolases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...